A combination vertical inhibition approach with inhibitors of SHP2 and ERK provides improved activity in KRAS-mutant pancreatic and colorectal cancer models. (October 2022) - Hindley, C.; Biondo, A.; Brothwood, J.; Dao, K.H.; Kandola, N.; Lyons, J.; Nakatsuru, Y.; Smyth, T.; Wagner, S.; Wallis, N.; Hearn, K.